Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05486468

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI)

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)

Sponsor: ANI Pharmaceuticals

Conditions Uveitis Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior

Interventions Sham Injection Yutiq 0.18 MG Drug Implant

Updated 6 times since 2022 Last updated: Aug 6, 2025 Started: Oct 5, 2022 Primary completion: Jul 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05486468, this PHASE3 trial focuses on Uveitis and Uveitis, Anterior and remains actively recruiting participants. Sponsored by ANI Pharmaceuticals, it has been updated 6 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3

Status: Unknown → Recruiting
Jan 2025 — Sep 2025 [monthly]

Unknown PHASE3

Status: Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Nov 2022 — Jul 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Sep 2022 — Nov 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ANI Pharmaceuticals
Eye Point Pharmaceuticals
Texas Retina Associates

Data source: Texas Retina Associates

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Plano, United States